Thymoquinone enhances cisplatin-response through direct tumor effects in a syngeneic mouse model of ovarian cancer

Journal of Ovarian Research

Dineo Khabele¹  Fiona Yull¹  Whitney Barham⁴  Jeanette Saskowski²  Andrew J. Wilson³ 

[1] Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA;Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Vanderbilt University School of Medicine, Nashville, TN, USA;Department of Obstetrics and Gynecology, Vanderbilt University Medical Center, B1100 Medical Center North, Nashville 37232, TN, USA;Department of Cancer Biology, Vanderbilt University Medical Center, Nashville, TN, USA

关键词: Cisplatin;    Thymoquinone;    Macrophages;    Syngeneic mouse model;    Ovarian cancer;    NF-κB activity;   

Others  :  1221231
DOI  :  10.1186/s13048-015-0177-8

 received in 2015-04-24, accepted in 2015-07-08,  发布年份 2015

【 摘 要 】

Background

Ovarian cancer is the most lethal gynecologic malignancy characterized by the frequent development of resistance to platinum chemotherapy. Finding new drug combinations to overcome platinum resistance is a key clinical challenge. Thymoquinone (TQ) is a component of black seed oil that exerts multiple anti-tumorigenic effects on cells, including inhibition of NF-κB and promotion of DNA damage. We aimed to determine whether TQ enhances cisplatin cytotoxicity in cultured ovarian cancer cells and in an established murine syngeneic model of ovarian cancer.

Methods

Ovarian cancer cell viability in vitro was measured by sulforhodamine B (SRB) assays, and drug interactions tested for synergism by isobologram analysis. ID8-NGL mouse ovarian cancer cells stably expressing an NF-κB reporter transgene were injected intra-peritoneally into C57BL/6 mice. After 30 day TQ and/or cisplatin treatment, we measured the following indices: tumor burden (ascites volume, number of peritoneal implants and mesenteric tumor mass); NF-κB reporter activity (luciferase assay); protein expression of the double-strand DNA break marker, pH2AX(ser139), the proliferation markers, Ki67/mib-1 and PCNA, and the apoptosis markers, cleaved caspase-3, cleaved PARP and Bax; and mRNA expression of NF-κB targets, TNF-α and IL-1β. Two-tailed Mann–Whitney tests were used for measuring differences between groups in mouse experiments.

Results

In SRB assays, TQ and cisplatin synergized in ID8-NGL cells. In mice, cisplatin significantly reduced cell proliferation and increased apoptosis in tumors, resulting in decreased overall tumor burden. Combining TQ with cisplatin further decreased these indices, indicating co-operative effects between the drugs. TQ treatment promoted cisplatin-induced pH2AX expression in cultured cells and in tumors. While NF-κB inhibition by TQ induced anti-tumor effects in vitro, we made the unexpected observation that TQ alone increased both tumor NF-κB activity and formation of ascites in vivo.

Conclusions

TQ enhanced cisplatin-mediated cytoxicity in ovarian cancer cells in vitro and in a mouse syngeneic model, effects associated with increased DNA damage. However, our results strongly caution that TQ treatment alone may have an overall deleterious effect in the immunocompetent host through stimulation of ascites. Since TQ is a potential candidate for future clinical trials in ovarian cancer patients, this finding has considerable potential relevance to the clinic.

【 授权许可】

   
2015 Wilson et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 4.

Fig. 5.

Fig. 6.

【 参考文献 】

• [1]Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015; 65(1):5-29.
• [2]Bast RC, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer. 2009; 9(6):415-28.
• [3]Muggia F. Platinum compounds 30 years after the introduction of cisplatin: implications for the treatment of ovarian cancer. Gynecol Oncol. 2009; 112(1):275-81.
• [4]Sethi G, Ahn KS, Aggarwal BB. Targeting nuclear factor-kappa B activation pathway by thymoquinone: role in suppression of antiapoptotic gene products and enhancement of apoptosis. Mol Cancer Res. 2008; 6(6):1059-70.
• [5]Ahmad A, Husain A, Mujeeb M, Khan SA, Najmi AK, Siddique NA et al.. A review on therapeutic potential of Nigella sativa: a miracle herb. Asian Pac J Trop Biomed. 2013; 3(5):337-52.
• [6]Rahmani AH, Alzohairy MA, Khan MA, Aly SM. Therapeutic implications of black seed and its constituent thymoquinone in the prevention of cancer through inactivation and activation of molecular pathways. Evid Based Complement Alternat Med. 2014; 2014:724658.
• [7]Abukhader MM. Thymoquinone in the clinical treatment of cancer: fact or fiction? Pharmacogn Rev. 2013; 7(14):117-20.
• [8]Hernandez L, Hsu SC, Davidson B, Birrer MJ, Kohn EC, Annunziata CM. Activation of NF-kappaB signaling by inhibitor of NF-kappaB kinase beta increases aggressiveness of ovarian cancer. Cancer Res. 2010; 70(10):4005-14.
• [9]Meylan E, Dooley AL, Feldser DM, Shen L, Turk E, Ouyang C et al.. Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. Nature. 2009; 462(7269):104-7.
• [10]Karin M. The IkappaB kinase–a bridge between inflammation and cancer. Cell Res. 2008; 18(3):334-42.
• [11]Balkwill F, Coussens LM. Cancer: an inflammatory link. Nature. 2004; 431(7007):405-6.
• [12]Aggarwal BB. Nuclear factor-kappaB: the enemy within. Cancer Cell. 2004; 6(3):203-8.
• [13]Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002; 420(6917):860-7.
• [14]Al-Amri AM, Bamosa AO. Phase I safety and clinical activity study of thymoquinone in patients with advanced refractory malignant disease. Shiraz E-Med J. 2009; 10(3):107-11.
• [15]Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O et al.. Molecular mechanisms of cisplatin resistance. Oncogene. 2012; 31(15):1869-83.
• [16]Miow QH, Tan TZ, Ye J, Lau JA, Yokomizo T, Thiery JP et al.. Epithelial-mesenchymal status renders differential responses to cisplatin in ovarian cancer. Oncogene. 2014.
• [17]Gilmore TD, Herscovitch M. Inhibitors of NF-kappaB signaling: 785 and counting. Oncogene. 2006; 25(51):6887-99.
• [18]DelloRusso C, Welcsh PL, Wang W, Garcia RL, King MC, Swisher EM. Functional characterization of a novel BRCA1-null ovarian cancer cell line in response to ionizing radiation. Mol Cancer Res. 2007; 5(1):35-45.
• [19]Wilson AJ, Holson E, Wagner F, Zhang YL, Fass DM, Haggarty SJ et al.. The DNA damage mark pH2AX differentiates the cytotoxic effects of small molecule HDAC inhibitors in ovarian cancer cells. Cancer Biol Ther. 2011; 12(6):484-93.
• [20]Wilson AJ, Lalani AS, Wass E, Saskowski J, Khabele D. Romidepsin (FK228) combined with cisplatin stimulates DNA damage-induced cell death in ovarian cancer. Gynecol Oncol. 2012; 127(3):579-86.
• [21]Wilson AJ, Barham W, Saskowski J, Tikhomirov O, Chen L, Lee HJ et al.. Tracking NF-kappaB activity in tumor cells during ovarian cancer progression in a syngeneic mouse model. J Ovarian Res. 2013; 6(1):63. BioMed Central Full Text
• [22]Wilson AJ, Liu AY, Roland J, Adebayo OB, Fletcher SA, Slaughter JC et al.. TR3 modulates platinum resistance in ovarian cancer. Cancer Res. 2013; 73(15):4758-69.
• [23]Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzym Regul. 1984; 22:27-55.
• [24]Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 2001; 25(4):402-8.
• [25]Everhart MB, Han W, Sherrill TP, Arutiunov M, Polosukhin VV, Burke JR et al.. Duration and intensity of NF-kappaB activity determine the severity of endotoxin-induced acute lung injury. J Immunol. 2006; 176(8):4995-5005.
• [26]Stathopoulos GT, Sherrill TP, Han W, Sadikot RT, Yull FE, Blackwell TS et al.. Host nuclear factor-kappaB activation potentiates lung cancer metastasis. Mol Cancer Res. 2008; 6(3):364-71.
• [27]Khabele D, Fadare O, Liu AY, Wilson AJ, Wass E, Osteen K et al.. An orthotopic model of platinum-sensitive high grade serous fallopian tube carcinoma. Int J Clin Exp Pathol. 2012; 5(1):37-45.
• [28]Khabele D, Son DS, Parl AK, Goldberg GL, Augenlicht LH, Mariadason JM et al.. Drug-induced inactivation or gene silencing of class I histone deacetylases suppresses ovarian cancer cell growth: implications for therapy. Cancer Biol Ther. 2007; 6(5):795-801.
• [29]Wilson AJ, Byun DS, Nasser S, Murray LB, Ayyanar K, Arango D et al.. HDAC4 promotes growth of colon cancer cells via repression of p21. Mol Biol Cell. 2008; 19(10):4062-75.
• [30]Connelly L, Barham W, Onishko HM, Sherrill T, Chodosh LA, Blackwell TS et al.. Inhibition of NF-kappa B activity in mammary epithelium increases tumor latency and decreases tumor burden. Oncogene. 2011; 30(12):1402-12.
• [31]Roepke M, Diestel A, Bajbouj K, Walluscheck D, Schonfeld P, Roessner A et al.. Lack of p53 augments thymoquinone-induced apoptosis and caspase activation in human osteosarcoma cells. Cancer Biol Ther. 2007; 6(2):160-9.
• [32]Gurung RL, Lim SN, Khaw AK, Soon JF, Shenoy K, Mohamed Ali S et al.. Thymoquinone induces telomere shortening, DNA damage and apoptosis in human glioblastoma cells. PLoS One. 2010; 5(8): Article ID e12124
• [33]Banath JP, Klokov D, MacPhail SH, Banuelos CA, Olive PL. Residual gammaH2AX foci as an indication of lethal DNA lesions. BMC Cancer. 2010; 10:4. BioMed Central Full Text
• [34]Karabela SP, Psallidas I, Sherrill TP, Kairi CA, Zaynagetdinov R, Cheng DS et al.. Opposing effects of bortezomib-induced nuclear factor-kappaB inhibition on chemical lung carcinogenesis. Carcinogenesis. 2012; 33(4):859-67.
• [35]Aghajanian C, Blessing JA, Darcy KM, Reid G, DeGeest K, Rubin SC et al.. A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2009; 115(2):215-20.